166 related articles for article (PubMed ID: 21107573)
1. Involvement of RhoA and RalB in geranylgeranyltransferase I inhibitor-mediated inhibition of proliferation and migration of human oral squamous cell carcinoma cells.
Hamada M; Miki T; Iwai S; Shimizu H; Yura Y
Cancer Chemother Pharmacol; 2011 Sep; 68(3):559-69. PubMed ID: 21107573
[TBL] [Abstract][Full Text] [Related]
2. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth.
Falsetti SC; Wang DA; Peng H; Carrico D; Cox AD; Der CJ; Hamilton AD; Sebti SM
Mol Cell Biol; 2007 Nov; 27(22):8003-14. PubMed ID: 17875936
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho.
Kusama T; Mukai M; Tatsuta M; Nakamura H; Inoue M
Int J Oncol; 2006 Jul; 29(1):217-23. PubMed ID: 16773203
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I.
Chan LN; Fiji HD; Watanabe M; Kwon O; Tamanoi F
PLoS One; 2011; 6(10):e26135. PubMed ID: 22028818
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
6. Involvement of RalB in the effect of geranylgeranyltransferase I on glioma cell migration and invasion.
Song X; Hua L; Xu Y; Fang Z; Wang Y; Gao J; Shi Q; Zhou X; Yu R
Clin Transl Oncol; 2015 Jun; 17(6):477-85. PubMed ID: 25573158
[TBL] [Abstract][Full Text] [Related]
7. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA.
Adnane J; Bizouarn FA; Qian Y; Hamilton AD; Sebti SM
Mol Cell Biol; 1998 Dec; 18(12):6962-70. PubMed ID: 9819384
[TBL] [Abstract][Full Text] [Related]
8. Terbinafine inhibits oral squamous cell carcinoma growth through anti-cancer cell proliferation and anti-angiogenesis.
Chien MH; Lee TS; Kao C; Yang SF; Lee WS
Mol Carcinog; 2012 May; 51(5):389-99. PubMed ID: 21563217
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells.
Virtanen SS; Sandholm J; Yegutkin G; Kalervo Väänänen H; Härkönen PL
Cell Biol Int; 2010 Aug; 34(8):815-26. PubMed ID: 20446922
[TBL] [Abstract][Full Text] [Related]
10. RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo.
Faried A; Faried LS; Kimura H; Nakajima M; Sohda M; Miyazaki T; Kato H; Usman N; Kuwano H
Eur J Cancer; 2006 Jul; 42(10):1455-65. PubMed ID: 16750623
[TBL] [Abstract][Full Text] [Related]
11. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
Kusama T; Mukai M; Tatsuta M; Matsumoto Y; Nakamura H; Inoue M
Clin Exp Metastasis; 2003; 20(6):561-7. PubMed ID: 14598891
[TBL] [Abstract][Full Text] [Related]
14. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
15. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Eps8 in oral squamous cell carcinoma promotes cell migration and invasion through integrin-dependent Rac1 activation.
Yap LF; Jenei V; Robinson CM; Moutasim K; Benn TM; Threadgold SP; Lopes V; Wei W; Thomas GJ; Paterson IC
Oncogene; 2009 Jul; 28(27):2524-34. PubMed ID: 19448673
[TBL] [Abstract][Full Text] [Related]
17. RhoA regulates G1-S progression of gastric cancer cells by modulation of multiple INK4 family tumor suppressors.
Zhang S; Tang Q; Xu F; Xue Y; Zhen Z; Deng Y; Liu M; Chen J; Liu S; Qiu M; Liao Z; Li Z; Luo D; Shi F; Zheng Y; Bi F
Mol Cancer Res; 2009 Apr; 7(4):570-80. PubMed ID: 19372585
[TBL] [Abstract][Full Text] [Related]
18. Stability of p21Waf1/Cip1 CDK inhibitor protein is responsive to RhoA-mediated regulation of the actin cytoskeleton.
Coleman ML; Densham RM; Croft DR; Olson MF
Oncogene; 2006 May; 25(19):2708-16. PubMed ID: 16407839
[TBL] [Abstract][Full Text] [Related]
19. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.
Lim KH; O'Hayer K; Adam SJ; Kendall SD; Campbell PM; Der CJ; Counter CM
Curr Biol; 2006 Dec; 16(24):2385-94. PubMed ID: 17174914
[TBL] [Abstract][Full Text] [Related]
20. Wnt5b promotes the cell motility essential for metastasis of oral squamous cell carcinoma through active Cdc42 and RhoA.
Takeshita A; Iwai S; Morita Y; Niki-Yonekawa A; Hamada M; Yura Y
Int J Oncol; 2014 Jan; 44(1):59-68. PubMed ID: 24220306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
